{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T21:32:48Z","timestamp":1773351168855,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002412","name":"Xi'an Jiaotong University","doi-asserted-by":"publisher","award":["2023-CX-PT-43"],"award-info":[{"award-number":["2023-CX-PT-43"]}],"id":[{"id":"10.13039\/501100002412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373956"],"award-info":[{"award-number":["82373956"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jtct.2025.09.043","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:01:21Z","timestamp":1759554081000},"page":"211.e1-211.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mining Safety Signals of Letermovir Drug Combinations: Real-World Pharmacovigilance Analysis"],"prefix":"10.1016","volume":"32","author":[{"given":"Jingjing","family":"Lan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengmeng","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiqi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jtct.2025.09.043_bib0001","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/ajt.15515","article-title":"Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (allo-HSCT): a systematic review, meta-analysis, and meta-regression analysis","volume":"19","author":"Gim\u00e9nez","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jtct.2025.09.043_bib0002","unstructured":"National library of medicine. DailyMed Prevymis letermovir tablet, film coated\u2014prevymis letermovir injection, solution Prevymis letermovir pellet. https:\/\/www.dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=1b49df80-be4f-47e0-a0b7-123f3e69395b. Accessed April 18, 2025."},{"issue":"12","key":"10.1016\/j.jtct.2025.09.043_bib0003","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jtct.2021.09.010","article-title":"American society for transplantation and cellular therapy series: #4\u2014cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation","volume":"27","author":"Yong","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2025.09.043_bib0004","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1097\/INF.0000000000004489","article-title":"Clinical practice guidelines for the management of congenital cytomegalovirus infection in Japan 2023: executive summary","volume":"43","author":"Ito","year":"2024","journal-title":"Pediatr Infect Dis J"},{"issue":"25","key":"10.1016\/j.jtct.2025.09.043_bib0005","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jtct.2025.09.043_bib0006","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","article-title":"American society for transplantation and cellular therapy series: #3\u2014prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation","volume":"27","author":"Hakki","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.043_bib0007","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cmi.2022.07.001","article-title":"Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium","volume":"29","author":"Khawaja","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.jtct.2025.09.043_bib0008","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.jtct.2025.09.043_bib0009","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/cid\/ciz490","article-title":"A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation","volume":"70","author":"Ljungman","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.043_bib0010","doi-asserted-by":"crossref","first-page":"105.e1","DOI":"10.1016\/j.jtct.2024.12.010","article-title":"Letermovir for prevention of recurrent cytomegalovirus in high-risk allogeneic hematopoietic cell transplantation recipients","volume":"31","author":"Han","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2025.09.043_bib0011","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40261-024-01376-w","article-title":"Real-world safety and effectiveness of letermovir in patients undergoing allogenic hematopoietic stem cell transplantation: final results of post-marketing surveillance in Japan","volume":"44","author":"Fukuda","year":"2024","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.043_bib0012","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4274\/tjh.galenos.2024.2024.0026","article-title":"Real-life data on the efficacy and safety of letermovir for primary prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients: a single-center analysis","volume":"41","author":"W\u0142odarczyk","year":"2024","journal-title":"Turk J Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.043_bib0013","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.043_bib0014","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","article-title":"Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS)","volume":"1","author":"Anand","year":"2019","journal-title":"JACC CardioOncol"},{"issue":"5","key":"10.1016\/j.jtct.2025.09.043_bib0015","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","article-title":"Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems","volume":"37","author":"Noguchi","year":"2020","journal-title":"Pharm Res"},{"issue":"16","key":"10.1016\/j.jtct.2025.09.043_bib0016","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1002\/sim.3247","article-title":"A statistical methodology for drug-drug interaction surveillance","volume":"27","author":"Nor\u00e9n","year":"2008","journal-title":"Stat Med"},{"issue":"11","key":"10.1016\/j.jtct.2025.09.043_bib0017","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1111\/bcp.14868","article-title":"Pharmacovigilance-based drug repurposing: the search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections","volume":"87","author":"B\u00f6hm","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jtct.2025.09.043_bib0018","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.jtct.2025.09.043_bib0019","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00228-017-2233-3","article-title":"Utilization of chi-square statistics for screening adverse drug-drug interactions in spontaneous reporting systems","volume":"73","author":"Gosho","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.043_bib0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40360-024-00772-4","article-title":"Safety assessment of asenapine in the FAERS database: real adverse event analysis and discussion on neurological and psychiatric side effects","volume":"25","author":"Jin","year":"2024","journal-title":"BMC Pharmacol Toxicol"},{"issue":"7","key":"10.1016\/j.jtct.2025.09.043_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002119","article-title":"Ocular adverse events in PD-1 and PD-L1 inhibitors","volume":"9","author":"Young","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.043_bib0022","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s10194-024-01913-0","article-title":"Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food And Drug Administration (FDA) adverse event reporting system (FAERS) database","volume":"25","author":"Liu","year":"2024","journal-title":"J Headache Pain"},{"key":"10.1016\/j.jtct.2025.09.043_bib0023","unstructured":"European medicines agency. Signal management | European Medicines Agency (EMA). https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/pharmacovigilance-post-authorisation\/signal-management. Accessed April 18, 2025."},{"key":"10.1016\/j.jtct.2025.09.043_bib0024","unstructured":"National library of medicine. DailyMed\u2014cyclosporine capsule, liquid filled. https:\/\/www.dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=64ec430a-e930-145c-e766-13fb49b64644. Accessed April 18, 2025."},{"issue":"1","key":"10.1016\/j.jtct.2025.09.043_bib0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10096-024-04977-7","article-title":"Role of letermovir therapeutic drug monitoring for cytomegalovirus prophylaxis in allogeneic hematopoietic stem cell transplantation recipients: a prospective study","volume":"44","author":"Qiu","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.jtct.2025.09.043_bib0026","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1177\/1078155218783245","article-title":"Letermovir associated hepatic transaminitis: a case report","volume":"25","author":"Geswein","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"10.1016\/j.jtct.2025.09.043_bib0027","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1093\/jac\/dkz218","article-title":"Letermovir in paediatric HSCT recipients","volume":"74","author":"Strenger","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.043_bib0028","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-024-01612-y","article-title":"Increased Epstein\u2012Barr virus reactivation following prophylaxis for cytomegalovirus infection after haploidentical haematopoietic stem cell transplantation","volume":"17","author":"Kong","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2025.09.043_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.666774","article-title":"Letermovir administration to prevent cytomegalovirus reactivation is the potential risk of chronic graft-versus-host disease in patients who received haploidentical stem-cell transplantation with post-transplant cyclophosphamide","volume":"11","author":"Terao","year":"2021","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2025.09.043_bib0030","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/bloodadvances.2024012849","article-title":"Immune milestones to predict CMV after letermovir","volume":"8","author":"Little","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2025.09.043_bib0031","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/bloodadvances.2023012008","article-title":"Impaired T cells and \u2018memory-like\u2019 NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessation","volume":"8","author":"Lauruschkat","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.043_bib0032","doi-asserted-by":"crossref","first-page":"8664","DOI":"10.1038\/s41467-024-52913-2","article-title":"The activating receptor NKG2D is an anti-fungal pattern recognition receptor","volume":"15","author":"Charpak-Amikam","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.043_bib0033","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.043_bib0034","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40360-024-00738-6","article-title":"Drug-drug interaction assessment based on a large-scale spontaneous reporting system for hepato- and renal-toxicity, and thrombocytopenia with concomitant low-dose methotrexate and analgesics use","volume":"25","author":"Honma","year":"2024","journal-title":"BMC Pharmacol Toxicol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:54:56Z","timestamp":1773312896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725014769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2666636725014769"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.043","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mining Safety Signals of Letermovir Drug Combinations: Real-World Pharmacovigilance Analysis","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Transplantation and Cellular Therapy. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}